Michael joined Brandon Capital in 2016.
Prior to joining Brandon Capital, Michael served as Senior Business Development Manager at Monash University, managing the Life Sciences portfolio for the Faculty of Medicine. In this role, he managed multiple opportunities that became collaborations and/or partnered assets with global pharmaceutical companies or emerging biotechnology firms.
Earlier in his career, Michael was an Investment Manager (Life Sciences) at TTCF, a seed and venture commercialisation fund supporting academic‑research‑driven innovation. He led due diligence and investment negotiations across several life sciences transactions, including Nexvet Biopharma (NASDAQ: NVET), which was acquired by Zoetis in 2017 for its lead monoclonal antibody asset, now marketed as Solensia.
Michael completed a Roche Research Foundation Postdoctoral Fellowship at ISREC (EPFL) in Lausanne, Switzerland. He holds a Bachelor of Science (First‑Class Honours) and a PhD in stem cell biology from the University of Adelaide, as well as an MBA in Technology Management from La Trobe University. He is also a graduate of the Australian Institute of Company Directors (AICD).
Michael is currently a Non-Executive Director of Cincera Therapeutics Pty Ltd, Currus Biologics Pty Ltd, Foray Therapeutics Pty Ltd and Mirugen Pty Ltd, and led due diligence for Brandon Capital’s recent investment in AdvanCell Isotopes Pty Ltd.
